

PTO-898 (01-08)

Approved for use through 08/30/2008. OMB 0551-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

*Complete if Known*

Application Number	10/700,816-Conf. #9864
Filing Date	November 4, 2003
First Named Inventor	Zuoshang XU
Art Unit	1635
Examiner Name	S. McGarry
Attorney Docket Number	UMY-038

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
A1*	US-20040175703	09-09-2004	Kreutzer et al.		

### FOREIGN PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>2</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
B1	DE-10155280.7		10-26-2001	Ribopharma AG et al.		✓
B2	DE-10158411.3		11-29-2001	Ribopharma AG et al.		✓
B3	DE-10160151.4		12-07-2001	Ribopharma AG et al.		✓
B4	DE-10235620.3		08-02-2002	Ribopharma AG		✓

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>2</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
B5	CA-242350-A1		07-18-2002	Ribopharma AG		
B6	CA-2432341-A1		07-18-2002	Ribopharma AG		
B7	WO-02/055692-A2		07-18-2002	Ribopharma AG et al.		Abstr.
B8	WO-02/055693-A2		07-18-2002	Ribopharma AG et al.		Abstr.
B9	WO-03/035869-A1		05-01-2003	Ribopharma AG et al.		✓
B10	DE-10160151-A1		06-26-2003	Ribopharma AG		✓

Examiner Signature	Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 606. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
C1	Gaudette, Mara et al., "Current status of SOD1 mutations in familial amyotrophic lateral sclerosis," <i>ALS</i> , Vol. 1:83-89 (2000)		
C2	Holen, Torgei et al., "Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor," <i>Nucleic Acids Research</i> , Vol. 30(8):1757-1766 (2002)		
C3	Kato, Shinsuke et al., "New consensus research on neuropathological aspects of familial amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) gene mutations: Inclusions containing SOD1 in neurons and astrocytes," <i>ALS</i> , Vol. 1:163-184 (2000)		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

PTO-SB/08b (01-08)

Approved for use through 06/30/2008. OMB 0551-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	2	Attorney Docket Number	UMY-038
-------	---	----	---	------------------------	---------

C4	Orrell, Richard et al., "Clinical implications of the genetics of ALS and other motor neuron diseases," <i>Neurology</i> , Vol. 57:9-17 (2001)	
C5	Radunović, Aleksandar et al., "ALSODatabase: Database of SOD1 (and other) gene mutations in ALS on the Internet," <i>Amyot. Lat. Scler.</i> , Vol. 1:45-49 (1999)	

Examiner Signature	/Sean Mcgarry/	Date Considered	07/23/2008
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.